Effect of an Anti-Oxidant Treatment on Resistin Serum Levels.A Randomized Study

This study has been terminated.
Sponsor:
Information provided by:
University of Turin, Italy
ClinicalTrials.gov Identifier:
NCT00387114
First received: October 10, 2006
Last updated: NA
Last verified: October 2006
History: No changes posted
  Purpose

The aim of the present study was to evaluate whether an in vivo treatment with an antioxidant vitamin (vitamin C) might substantially affect serum levels of resistin, a recently described adipokine, whose clinical significance is still controversial in humans.


Condition Intervention Phase
Metabolic Diseases
Oxidative Stress
Drug: Vitamin C
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Effect of an Anti-Oxidant Treatment on Resistin Serum Levels.A Randomized Study

Resource links provided by NLM:


Further study details as provided by University of Turin, Italy:

Primary Outcome Measures:
  • Mean resistin serum level reduction, after vitamin C treatment, of at least 0.50 standardized units.

Secondary Outcome Measures:
  • The within- and between-group variations in the other inflammatory and oxidative variables measured.

Estimated Enrollment: 80
Study Start Date: June 2005
Estimated Study Completion Date: November 2005
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   20 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • age 20-50 years
  • absence of known hyperglycemia, hypertension, cardiovascular disease, impaired renal function, liver disease, or any other systemic conditions no use of any drug, estrogen included
  • not being on a particular diet and/or vitamin or other nutrient supplementation

Exclusion Criteria:

  • actual pregnancy
  • known hyperglycemia, hypertension, cardiovascular disease, impaired renal function, liver disease, or any other systemic conditions
  • use of any drug, estrogen included
  • being on a particular diet, vitamin or other nutrient supplementation
  • history of renal calculi.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00387114

Locations
Italy
Department of Internal Medicine, University of Turin
Turin, Italy, 10126
Sponsors and Collaborators
University of Turin, Italy
Investigators
Principal Investigator: Gianfranco Pagano, MD University of Turin
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00387114     History of Changes
Other Study ID Numbers: 2005-002368-27
Study First Received: October 10, 2006
Last Updated: October 10, 2006
Health Authority: Italy: National Monitoring Centre for Clinical Trials - Ministry of Health

Keywords provided by University of Turin, Italy:
C-reactive protein
nitrotyrosine
oxidative stress
resistin
vitamin C

Additional relevant MeSH terms:
Metabolic Diseases
Vitamins
Antioxidants
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Molecular Mechanisms of Pharmacological Action
Protective Agents

ClinicalTrials.gov processed this record on September 16, 2014